Obsessive-Compulsive DisorderNCT04730011
Short and Intensive Treatment of Children and Adolescents With Obsessive-Compulsive Disorder
A study testing Short and Intensive Treatment in people with Obsessive-Compulsive Disorder, run by Susanne Walitza at 1 site in Switzerland.
Trial summary
Obsessive-compulsive disorders are very damaging illnesses; they can already appear in childhood and adolescence and become extremely chronic. With an average prevalence from 1-3%, they are among the most common psychiatric disorders in children and adolescents. Read more about this study
- Who is it for?
- Ages 8 to 18 years
- Conditions the study is for
- Obsessive-Compulsive Disorder
- What is being tested?
- Short and Intensive Treatment
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 100 participants
- Where
- 1 siteSwitzerland
- Study dates
- 1 Jan 2021to 31 Dec 2028
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 8 to 18 years
- All sexes
- No healthy volunteers
- Child, Adult
Who may be able to join
- Obsessive-Compulsive Disorder diagnosis
- Male and female patients from 8-18 years
- Good German language speaking skills
- IQ of at least 75
- At least four days' participation in the treatment/therapy week
- Written agreement after clear explanation
Who cannot join
- No complete participation in the intensive week treatment/therapy
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Switzerland1 site, 1 recruiting
- Recruiting
Psychiatric University Clinics, Department of Child and Adolescent Psychiatry
Zurich, Canton of Zurich, 8032
Susanne Walitza, Prof. Dr. med. Dipl.-Psych., +41 43 499 26 26, susanne.walitza@puk.zh.ch
About this study
Official title: Short and Intensive Treatment of Children and Adolescents With Obsessive-Compulsive Disorder - A Study to Evaluate the Effectiveness of an Intensive Treatment Week: "A Future Without Constraint"
Obsessive-compulsive disorders are very damaging illnesses; they can already appear in childhood and adolescence and become extremely chronic. With an average prevalence from 1-3%, they are among the most common psychiatric disorders in children and adolescents. 40% of diagnosed children and young adults display persistent and increasingly chronic symptoms and O-C disorders are highly complex syndromes with broadly varying manifestations. They arise from obsessive thoughts (ideas/thoughts or impulses, often senseless or tortured, that impose themselves or intrude) and obsessive behavior (ritualized patterns that must be frequently repeated).
- Conditions
- Obsessive-Compulsive Disorder
- Being tested
- Short and Intensive Treatment
- Medical subject headings
- Obsessive-Compulsive Disorder
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Short and Intensive TreatmentBehavioural
Intensive Treatment Week with behavioural psychotherapy
| Study group | Role | What they receive |
|---|---|---|
| Treatment Group | Experimental | Patients are treated based on the Cognitive Behavioral Psychotherapy. This includes individual and group sessions over one week. Receives: Behavioral: Short and Intensive Treatment |
What is being measured
The primary outcome is the main question the study is designed to answer.
Symptoms severity of obsessive and compulsive symptoms in children and adolescents
The clinician-report questionnaire (BY-BOCS) contains 19 items designed to assess severity of obsessive and compulsive symptoms in children and adolescents.The test uses a 4-point scale to rate the severity of their obsessive compulsive behaviors. Higher score means a worse outcome.
Measured: 12 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted29 Jan 2021
- Study start1 Jan 2021
- Primary completion31 Dec 2028 (estimated)
- Study completion31 Dec 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Obsessive-Compulsive DisorderStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 100 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Susanne Walitza
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor-investigator, Susanne Walitza, Psychiatric University Hospital, Zurich
- Investigators
- Susanne Walitza, Prof. Dr. med. Dipl.-Psych., Principal investigator, Sponsor GmbH
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04730011
- Sponsor's protocol ID
- KJPP 2020-02053
- Status last verified
- May 2025
- First submitted
- 25 Jan 2021
- Last updated
- 13 May 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 13 May 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Short and Intensive Treatment of Children and Adolescents With Obsessive-Compulsive Disorder - A Study to Evaluate the Effectiveness of an Intensive Treatment Week: "A Future Without Constraint"
- ClinicalTrials.gov ID
- NCT04730011
- Acronym / sponsor ID
- KJPP 2020-02053
- Conditions
- Obsessive-Compulsive Disorder
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 100 participants (estimated)
- Lead sponsor
- Susanne WalitzaUniversity, hospital or other
- Study start
- 1 Jan 2021 (actual)
- Primary completion
- 31 Dec 2028 (estimated)
- Study completion
- 31 Dec 2028 (estimated)
- First posted
- 29 Jan 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Obsessive-compulsive disorders are very damaging illnesses; they can already appear in childhood and adolescence and become extremely chronic. With an average prevalence from 1-3%, they are among the most common psychiatric disorders in children and adolescents. 40% of diagnosed children and young adults display persistent and increasingly chronic symptoms and O-C disorders are highly complex syndromes with broadly varying manifestations. They arise from obsessive thoughts (ideas/thoughts or impulses, often senseless or tortured, that impose themselves or intrude) and obsessive behavior (ritualized patterns that must be frequently repeated).
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Treatment Group | Experimental | Behavioral: Short and Intensive TreatmentPatients are treated based on the Cognitive Behavioral Psychotherapy. This includes individual and group sessions over one week. |
Who may qualify
- Ages
- 8 to 18 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult
Key inclusion criteria (6 listed)
- Obsessive-Compulsive Disorder diagnosis
- Male and female patients from 8-18 years
- Good German language speaking skills
- IQ of at least 75
- At least four days' participation in the treatment/therapy week
Key exclusion criteria (1 listed)
- No complete participation in the intensive week treatment/therapy
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Short and Intensive TreatmentIntensive Treatment Week with behavioural psychotherapy | Behavioural | Treatment Group |
Primary outcome
Symptoms severity of obsessive and compulsive symptoms in children and adolescents
Time frame: 12 months
The clinician-report questionnaire (BY-BOCS) contains 19 items designed to assess severity of obsessive and compulsive symptoms in children and adolescents.The test uses a 4-point scale to rate the severity of their obsessive compulsive behaviors. Higher score means a worse outcome.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 13 May 2025.
- Individual participant dataSharing planned: No
Related trials for Obsessive-Compulsive Disorder
Enrolling by invitation
Family Accommodation Reduction in Adult Obsessive Compulsive Disorder
Obsessive - Compulsive Disorder, Family Accommodation
Not yet recruitingObservational study
Investigation of Obsessive-Compulsive Disorder in Patients With Elbow Epicondylitis
Lateral Epicondylitis, Medial Epicondylitis
Recruiting
Precision Analytic Research Methods in OCD
Obsessive Compulsive Disorder
Recruiting
Focused Ultrasound for Behavioral Health
Depression, Anxiety
Not yet recruiting
Linear Accelerator Radiosurgical Anterior Capsulotomy With Task-based fMRI Identification of PERSonalized and PrEdictiVE Biomarkers of REsponse in Treatment-Refractory Obsessive-Compulsive Disorder (PERSEVERE Trial)
Treatment-refractory Obsessive-compulsive Disorder (trOCD)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Susanne Walitza, Prof. Dr. med. Dipl.-Psych. principal investigator
Sponsor GmbH
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Short and Intensive Treatment in people with Obsessive-Compulsive Disorder, run by Susanne Walitza at 1 site in Switzerland.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 13 May 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Switzerland. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Susanne Walitza, Prof. Dr. med. Dipl.-Psych. (+41 (0)43 499 26 26, susanne.walitza@puk.zh.ch), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Symptoms severity of obsessive and compulsive symptoms in children and adolescents (time frame: 12 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 May 2025.